Folgen
Keine Story von Santaris Pharma A/S mehr verpassen.

Santaris Pharma A/S

Filtern
  • 20.03.2009 – 13:12

    Another LNA-based RNA Inhibitor Enters Clinical Trials

    Copenhagen (ots/PRNewswire) - - EZN3042 - a Survivin Inhibitor Jointly Developed by Enzon Pharmaceuticals and Santaris Pharma Advances into the Clinic for Patients With Solid Tumors and Lymphomas Santaris Pharma announced today that the fourth LNA-based drug has been brought into the clinic. In the USA several patients with cancer have now been treated with the Company's Survivin inhibitor, which is jointly ...